Saund Saran 4
4 · Oncotelic Therapeutics, Inc. · Filed Sep 8, 2021
Insider Transaction Report
Form 4
Saund Saran
CHIEF BUSINESS OFFICER
Transactions
- Award
Stock Options
2021-09-03+675,000→ 675,000 totalExercise: $0.14Exp: 2031-09-03→ Common Stock (675,000 underlying)
Footnotes (1)
- [F1]Stock Options vest as follows: (i) 50% of the options will vest upon the consummation of a qualifying joint venture agreement, licensing agreement, or acquisition transaction (a "Corporate Transaction"); (ii) The remaining 50% on the one-year anniversary of the consummation of a Corporate Transaction.